Considering many synucleinopathies involve the accumulation of α-syn in neurons, astrocytes and oligodendroglial cells and involve the propagation of α-syn from cell-to-cell, the use of NR-R80Q-apoB should be considered a potential therapeutic for other synucleinopathies such as PD and DLB. This evidence concerns the gene APOB and Parkinson disease.